ATE543818T1 - -n(2-hydroxyethyl)-n-methyl-4-(chinolin-8-yl-(1 (thiazol-4-ylmethyl)piperidin-4- yliden)methyl)benzamid, verfahren zu dessen herstellung sowie dessen verwendung zur behandlung von schmerzen, angst und depression - Google Patents

-n(2-hydroxyethyl)-n-methyl-4-(chinolin-8-yl-(1 (thiazol-4-ylmethyl)piperidin-4- yliden)methyl)benzamid, verfahren zu dessen herstellung sowie dessen verwendung zur behandlung von schmerzen, angst und depression

Info

Publication number
ATE543818T1
ATE543818T1 AT07835125T AT07835125T ATE543818T1 AT E543818 T1 ATE543818 T1 AT E543818T1 AT 07835125 T AT07835125 T AT 07835125T AT 07835125 T AT07835125 T AT 07835125T AT E543818 T1 ATE543818 T1 AT E543818T1
Authority
AT
Austria
Prior art keywords
methyl
chinoline
ylidene
thiazol
benzamide
Prior art date
Application number
AT07835125T
Other languages
German (de)
English (en)
Inventor
Khanh Bui
Cathy Dantzman
Glen Ernst
Valerie Hoesch
Thomas Hudzik
Megan King
Jie Liu
Jingbo Yan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE543818T1 publication Critical patent/ATE543818T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT07835125T 2006-10-20 2007-10-19 -n(2-hydroxyethyl)-n-methyl-4-(chinolin-8-yl-(1 (thiazol-4-ylmethyl)piperidin-4- yliden)methyl)benzamid, verfahren zu dessen herstellung sowie dessen verwendung zur behandlung von schmerzen, angst und depression ATE543818T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20
PCT/SE2007/000924 WO2008048171A1 (en) 2006-10-20 2007-10-19 N- (2 -hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression.

Publications (1)

Publication Number Publication Date
ATE543818T1 true ATE543818T1 (de) 2012-02-15

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07835125T ATE543818T1 (de) 2006-10-20 2007-10-19 -n(2-hydroxyethyl)-n-methyl-4-(chinolin-8-yl-(1 (thiazol-4-ylmethyl)piperidin-4- yliden)methyl)benzamid, verfahren zu dessen herstellung sowie dessen verwendung zur behandlung von schmerzen, angst und depression

Country Status (32)

Country Link
US (2) US7659286B2 (OSRAM)
EP (1) EP2079735B1 (OSRAM)
JP (1) JP4668346B2 (OSRAM)
KR (1) KR20090065534A (OSRAM)
CN (1) CN101528739B (OSRAM)
AR (1) AR063345A1 (OSRAM)
AT (1) ATE543818T1 (OSRAM)
AU (2) AU2007313515B2 (OSRAM)
BR (1) BRPI0717631A2 (OSRAM)
CA (1) CA2667041C (OSRAM)
CL (1) CL2007003009A1 (OSRAM)
CO (1) CO6180450A2 (OSRAM)
CY (1) CY1112718T1 (OSRAM)
DK (1) DK2079735T3 (OSRAM)
ES (1) ES2379519T3 (OSRAM)
HR (1) HRP20120344T1 (OSRAM)
IL (1) IL197876A0 (OSRAM)
MX (1) MX2009003974A (OSRAM)
MY (1) MY148880A (OSRAM)
NO (1) NO20091969L (OSRAM)
NZ (1) NZ577060A (OSRAM)
PE (2) PE20080892A1 (OSRAM)
PL (1) PL2079735T3 (OSRAM)
PT (1) PT2079735E (OSRAM)
RS (1) RS52260B (OSRAM)
RU (1) RU2454414C2 (OSRAM)
SA (1) SA07280549B1 (OSRAM)
SI (1) SI2079735T1 (OSRAM)
TW (1) TW200826939A (OSRAM)
UA (1) UA97648C2 (OSRAM)
UY (1) UY30652A1 (OSRAM)
WO (1) WO2008048171A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641757A1 (en) * 2003-05-16 2006-04-05 AstraZeneca AB Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
BRPI0912756A2 (pt) * 2008-05-20 2015-10-13 Astrazeneca Ab método para tratar transtorno depressivo maior ansioso em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2016099393A1 (en) * 2014-12-19 2016-06-23 Pharmnovo Ab Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
EP3853435B1 (en) 2018-09-21 2024-08-21 Garland Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2009799A (en) * 1997-12-24 1999-07-19 Ortho-Mcneil Pharmaceutical, Inc. 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
AU784848B2 (en) 1999-12-20 2006-07-06 Zalicus Pharmaceuticals Ltd. Partially saturated calcium channel blockers
CN1426411A (zh) * 2000-03-03 2003-06-25 奥索-麦克尼尔药品公司 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
EP1641757A1 (en) * 2003-05-16 2006-04-05 AstraZeneca AB Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) * 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
CY1112718T1 (el) 2016-02-10
TW200826939A (en) 2008-07-01
EP2079735A4 (en) 2010-12-29
EP2079735A1 (en) 2009-07-22
CL2007003009A1 (es) 2008-06-06
ES2379519T3 (es) 2012-04-26
EP2079735B1 (en) 2012-02-01
RU2009111337A (ru) 2010-11-27
HK1131556A1 (en) 2010-01-29
IL197876A0 (en) 2009-12-24
KR20090065534A (ko) 2009-06-22
CA2667041C (en) 2011-09-06
CA2667041A1 (en) 2008-04-24
RU2454414C2 (ru) 2012-06-27
AR063345A1 (es) 2009-01-21
SA07280549B1 (ar) 2010-09-29
AU2007313515A1 (en) 2008-04-24
PL2079735T3 (pl) 2012-07-31
CN101528739B (zh) 2011-11-30
MX2009003974A (es) 2009-04-27
RS52260B (sr) 2012-10-31
PE20140634A1 (es) 2014-06-19
JP2010506910A (ja) 2010-03-04
PT2079735E (pt) 2012-05-07
UY30652A1 (es) 2008-05-31
US20080182875A1 (en) 2008-07-31
MY148880A (en) 2013-06-14
US20100160374A1 (en) 2010-06-24
BRPI0717631A2 (pt) 2013-10-29
WO2008048171A1 (en) 2008-04-24
SI2079735T1 (sl) 2012-05-31
CO6180450A2 (es) 2010-07-19
UA97648C2 (ru) 2012-03-12
NZ577060A (en) 2011-01-28
US7659286B2 (en) 2010-02-09
HRP20120344T1 (hr) 2012-05-31
NO20091969L (no) 2009-05-20
AU2010226996A1 (en) 2010-10-28
JP4668346B2 (ja) 2011-04-13
DK2079735T3 (da) 2012-05-21
PE20080892A1 (es) 2008-09-11
US7977355B2 (en) 2011-07-12
AU2007313515B2 (en) 2010-11-25
CN101528739A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
ATE543818T1 (de) -n(2-hydroxyethyl)-n-methyl-4-(chinolin-8-yl-(1 (thiazol-4-ylmethyl)piperidin-4- yliden)methyl)benzamid, verfahren zu dessen herstellung sowie dessen verwendung zur behandlung von schmerzen, angst und depression
DE50207943D1 (de) Kristallines anticholinergikum, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
ATE420866T1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
EP1626730A4 (en) METHOD, DEVICE AND COMPOSITION FOR TREATING ACNE
ATE518841T1 (de) Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602007008494D1 (de) Verwendung von Agomelatin zur Herstellung von Medikamenten zur Behandlung der generalisierten Angststörung
ATE407921T1 (de) Neues verfahren zur herstellung und eine neue kristallform des agomelatins sowie pharmazeutische zusammensetzungen, die diese enthalten
SI2937341T1 (sl) Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj
DE602005018981D1 (de) Verfahren zur Herstellung von L-Cystein, und L-Cystein-produzierender Mikroorganismus
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE303379T1 (de) 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
EP1651237A4 (en) METHODS OF TREATING DERMATOLOGICAL DISORDERS
ATE390130T1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
EP1592464A4 (en) METHOD OF TREATING COGNITIVE DECLINE FROM LACK OF SLEEP AND STRESS
EP2151426A4 (en) PROCESS FOR PRODUCTION OF 1,5-PENTANEDIOL AND / OR 1,6-HEXANEDIOL
DE60308045D1 (de) Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes
DE50206824D1 (de) Befestigungselement und verfahren zu seiner herstellung sowie verwendung
ATE287400T1 (de) 4-(phenylpiperidin-4-ylidenmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE313528T1 (de) 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen,angst oder gastrointestinalen störungen
ATE313529T1 (de) 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen,angst oder gastrointestinalen störungen
FR2903098B1 (fr) Nouvelle forme d'hydroquinone et son procede d'obtention
DE602005015611D1 (de) Temperaturempfindliches und biologisch kompatibles amphiphiles cyclisches phosphazentrimer und verfahren zu dessen herstellung
DE502005010129D1 (de) Verfahren zur herstellung von vliesstoffen, vliesstoff und dessen verwendung